Literature DB >> 21912418

Targeted therapies: Congratulations, you are still in the running towards becoming ovarian-next-top treatment.

M Teresa Villanueva.   

Abstract

Year:  2011        PMID： 21912418     DOI： 10.1038/nrclinonc.2011.138

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

Authors:  Jonathan A Ledermann; Allan Hackshaw; Stan Kaye; Gordon Jayson; Hani Gabra; Iain McNeish; Helena Earl; Tim Perren; Martin Gore; Mojca Persic; Malcolm Adams; Lindsay James; Graham Temple; Michael Merger; Gordon Rustin
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544
  1 in total
  2 in total

1.  Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma.

Authors:  Chengkuan Cai; Jingyuan Tang; Baixin Shen; Liucheng Ding; Yunpeng Shao; Zhengsen Chen; Yinchao Ma; Haoliang Xue; Zhongqing Wei
Journal:  Exp Ther Med       Date:  2017-07-31       Impact factor: 2.447

2.  Dexamethasone and lenvatinib inhibit migration and invasion of non-small cell lung cancer by regulating EKR/AKT and VEGF signal pathways.

Authors:  Daye Zhang; Yongxiang Zhang; Zeyuan Cai; Ying Tu; Zhansong Hu
Journal:  Exp Ther Med       Date:  2019-11-21       Impact factor: 2.447
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.